Arcturus Therapeutics
RNA medicines company — LUNAR LNP platform enabling self-amplifying mRNA for vaccines (ARCT-154 approved in Japan) and liver-targeted RNA therapeutics.
- Country
- United States
- Revenue
- ~$20M
- Employees
- 111 emp
FDA GMP
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| mRNA platforms & LNP delivery | therapeutics-platforms | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.